Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 5.2% Following Analyst Downgrade

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) shares traded down 5.2% during mid-day trading on Tuesday after Guggenheim lowered their price target on the stock from $40.00 to $38.00. Guggenheim currently has a buy rating on the stock. Olema Pharmaceuticals traded as low as $15.63 and last traded at $15.7360. 362,758 shares changed hands during trading, a decline of 77% from the average session volume of 1,607,136 shares. The stock had previously closed at $16.60.

A number of other analysts also recently weighed in on OLMA. JPMorgan Chase & Co. increased their target price on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Stifel Nicolaus began coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, February 11th. They issued a “buy” rating and a $48.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Thursday, January 22nd. UBS Group began coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, January 7th. They set a “buy” rating and a $45.00 target price for the company. Finally, HC Wainwright dropped their target price on shares of Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.22.

Insider Activity

In other Olema Pharmaceuticals news, insider Naseem Zojwalla sold 99,509 shares of the firm’s stock in a transaction dated Tuesday, December 23rd. The stock was sold at an average price of $27.66, for a total transaction of $2,752,418.94. Following the sale, the insider owned 4,488 shares in the company, valued at $124,138.08. This trade represents a 95.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Shane William Charles Kovacs sold 100,000 shares of Olema Pharmaceuticals stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $28.73, for a total value of $2,873,000.00. Following the sale, the insider directly owned 139,727 shares of the company’s stock, valued at approximately $4,014,356.71. This trade represents a 41.71% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 805,501 shares of company stock worth $23,003,832. Corporate insiders own 16.36% of the company’s stock.

Key Headlines Impacting Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Company update: Olema reiterated clinical progress and strong cash position — OPERA‑01 pivotal top‑line readout still on track for fall 2026, OPERA‑02 enrollment advanced, a Phase 1b/2 combo study with Pfizer’s atirmociclib was initiated, OP‑3136 enrollment continues with initial data expected in Q2 2026, and the company ended 2025 with $505.4M in cash after raising $218.5M in a follow‑on offering. These items materially de‑risk near‑term financing and support runway into late‑stage catalysts. Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
• Positive Sentiment: Earnings beat (small): Olema reported Q4 EPS of ($0.50), narrowly beating consensus of ($0.51). The modest beat appears to have supported a short‑term rally yesterday. View Press Release
• Positive Sentiment: Bullish analyst action: Citigroup raised its price target from $60 to $62 and maintained a Buy rating, implying substantial upside vs. current levels — a supportive read for longer‑term holders. Benzinga
• Neutral Sentiment: Analyst revision with mixed tone: Guggenheim trimmed its price target from $40 to $38 but kept a Buy rating, a mild pullback in expectations that still signals conviction in the thesis. Benzinga
• Negative Sentiment: Near‑term selling pressure: Shares fell today after a notable intraday jump yesterday (around a 9% move) following the earnings surprise — the pullback looks consistent with profit‑taking after the rally and the mixed analyst actions (Guggenheim’s lower PT). The combination of short‑term traders taking gains and differing analyst targets is likely weighing on the stock despite operational positives. Olema Pharmaceuticals (OLMA) Stock Jumps 9% Following Fourth Quarter Earnings Surprise

Hedge Funds Weigh In On Olema Pharmaceuticals

A number of large investors have recently modified their holdings of OLMA. Ameritas Investment Partners Inc. lifted its position in Olema Pharmaceuticals by 55.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after buying an additional 2,168 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Olema Pharmaceuticals by 9,476.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after acquiring an additional 1,232 shares during the last quarter. Torren Management LLC purchased a new position in shares of Olema Pharmaceuticals during the fourth quarter worth approximately $44,000. Russell Investments Group Ltd. purchased a new position in shares of Olema Pharmaceuticals during the third quarter worth approximately $53,000. Finally, American Century Companies Inc. bought a new stake in shares of Olema Pharmaceuticals in the 2nd quarter worth approximately $54,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Olema Pharmaceuticals Trading Down 9.3%

The stock has a market capitalization of $1.03 billion, a P/E ratio of -8.10 and a beta of 1.92. The stock’s fifty day moving average price is $23.81 and its two-hundred day moving average price is $18.73. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Monday, March 16th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.01. Equities research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.